Loading organizations...
Venture capital and private investment firm investing in biopharma and medical device companies for medical innovation.
Get email updates
Join 25K+ founders & VCs who start their week informed.
Boston-based Bain Capital Life Sciences is a venture capital and private equity firm that invests globally in biopharmaceutical, medical device, diagnostic, and life science tool companies. Operating as a dedicated business unit of Bain Capital, which manages approximately $185 billion in total assets under management, the firm deploys capital across early-stage clinical startups and mature commercial enterprises. The firm typically makes equity investments ranging from $25 million to $100 million per portfolio company and recently closed its fourth dedicated life sciences fund with $3 billion in capital commitments in February 2024. Its investment portfolio features prominent healthcare and biotechnology companies, including Nuvalent, Amylyx Pharmaceuticals, SpringWorks Therapeutics, and Cerevel Therapeutics, which was notably acquired by AbbVie for $8.7 billion. Bain Capital Life Sciences was founded in 2016 by managing directors Adam Koppel and Jeffrey Schwartz.
Key people at Bain Capital Life Sciences.
Key people at Bain Capital Life Sciences.
Bain Capital Life Sciences is a specialized investment firm focused on advancing medical innovation by investing globally in biopharmaceutical, medical device, diagnostic, and life science tool companies. Their mission centers on improving patient outcomes by targeting companies that address unmet medical needs. The firm pursues a range of investment opportunities including inflection capital, growth capital, fallen angels, and private equity collaborations, supporting companies at various stages from clinical development to commercialization. Bain Capital Life Sciences leverages deep industry expertise and the broader Bain Capital platform to provide strategic and operational support, thereby fostering growth and innovation within the life sciences ecosystem[1][2].
Founded in 2016 (or 2017 according to some sources), Bain Capital Life Sciences emerged as a sector-focused arm of Bain Capital, building on the parent firm’s extensive history in healthcare and life sciences investing. The founding team comprises professionals with senior experience in both life sciences industries and healthcare investing, combining clinical insights with investment acumen. Over time, the firm has evolved to emphasize a broad spectrum of life sciences sectors, including pharmaceuticals, biotechnology, medical devices, diagnostics, and life science tools, reflecting the growing complexity and opportunity within the healthcare innovation landscape[1][2][3].
Bain Capital Life Sciences is positioned to capitalize on the accelerating trend of medical innovation driven by advances in biotechnology, personalized medicine, and medical devices. The timing is favorable due to increasing global demand for novel therapies addressing unmet medical needs, regulatory advancements, and growing healthcare investments. By supporting companies that develop cutting-edge therapies and technologies, the firm influences the broader ecosystem by enabling faster patient access to transformative treatments and fostering a robust innovation pipeline within life sciences[1][2][3].
Looking ahead, Bain Capital Life Sciences is likely to continue expanding its portfolio across emerging areas such as gene editing, cell therapies, and digital health tools, aligning with evolving scientific breakthroughs and healthcare demands. Trends such as precision medicine, biologics, and integrated diagnostics will shape their investment focus. Their influence is expected to grow as they deepen partnerships with management teams and leverage operational expertise to scale innovations globally, reinforcing their role as a key driver of life sciences advancement and patient impact[1][2][3].
Bain Capital Life Sciences has more than 26 tracked investments across 22 companies. The latest tracked deal is $100.0M Other Equity in Imperative Care in March 2026.
